| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Arteaga, Carlos |
| dc.contributor.author | Rojo, Federico |
| dc.contributor.author | Gonzalez-Perez, Abel |
| dc.contributor.author | Albanell, Joan |
| dc.contributor.author | Gamez-Pozo, Angelo |
| dc.contributor.author | Bellet Ezquerra, Meritxell |
| dc.date.accessioned | 2025-08-12T07:57:37Z |
| dc.date.available | 2025-08-12T07:57:37Z |
| dc.date.issued | 2025-06-20 |
| dc.identifier.citation | Albanell J, Gámez Pozo A, Arteaga CL, Bellet M, Rojo F, González A, et al. Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial. npj Breast Cancer. 2025 Jun 20;11:59. |
| dc.identifier.issn | 2374-4677 |
| dc.identifier.uri | http://hdl.handle.net/11351/13527 |
| dc.description | Biomarcadores; Cáncer de mama avanzado; Receptor hormonal positivo |
| dc.language.iso | eng |
| dc.publisher | Nature Portfolio |
| dc.relation.ispartofseries | npj Breast Cancer;11 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Marcadors bioquímics |
| dc.subject | Proteïnes quinases - Inhibidors - Ús terapèutic |
| dc.subject | Mama - Càncer - Tractament |
| dc.subject | Quimioteràpia combinada |
| dc.subject.mesh | Biomarkers |
| dc.subject.mesh | Protein Kinase Inhibitors |
| dc.subject.mesh | /therapeutic use |
| dc.subject.mesh | Breast Neoplasms |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
| dc.title | Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1038/s41523-025-00777-0 |
| dc.subject.decs | biomarcadores |
| dc.subject.decs | inhibidores de proteínas cinasas |
| dc.subject.decs | /uso terapéutico |
| dc.subject.decs | neoplasias de la mama |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
| dc.relation.publishversion | https://doi.org/10.1038/s41523-025-00777-0 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Albanell J] Hospital del Mar Research Institute Barcelona, Depatment of Medical Oncology, Hospital del Mar, Barcelona, Spain. Universitat Pompeu Fabra, Barcelona, Spain. Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. [Gámez Pozo A] Translational Oncology Lab, University Hospital La Paz - IdiPAZ, Madrid, Spain. [Arteaga CL] UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. [Bellet M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rojo F, González A] Hospital del Mar Research Institute Barcelona, Depatment of Medical Oncology, Hospital del Mar, Barcelona, Spain |
| dc.identifier.pmid | 40541946 |
| dc.identifier.wos | 001512768100002 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |